-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RZvfM7rrUp0aDY5y3jfyKvtn48J4ydKEvkGvkLtEmBPtSbjB0il+onJfDDNABY05 wxNaXnCkaEbFwnwNmv+uhA== 0001048477-02-000025.txt : 20020424 0001048477-02-000025.hdr.sgml : 20020424 ACCESSION NUMBER: 0001048477-02-000025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020430 ITEM INFORMATION: Other events FILED AS OF DATE: 20020424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 02618963 BUSINESS ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4158846700 MAIL ADDRESS: STREET 1: 371 BEL MARIN KEYS BLVD STREET 2: STE 210 CITY: NOVATO STATE: CA ZIP: 94949 8-K 1 bmrn8k021.txt 8-K ARYPLASE PRESS RELEASE ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2002 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 000-26727 68-0397820 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 371 Bel Marin Keys Boulevard, Suite 210, Novato, California 94949 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (415) 884-6700 Not Applicable ------------------------------------------------------------ (Former name or former address, if changed since last report) ================================================================================ ================================================================================ Item 5. Other Events. On April 22, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") announced the initiation of a Phase 2 clinical trial of Aryplase (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B) . The Registrant's press release issued on April 22, 2002 is attached hereto as Exhibit 99.1. Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. Not Applicable. (b) Pro Forma Financial Information. Not Applicable. (c) Exhibits. Exhibit 99.1 Press Release of the Registrant dated April 22, 2002 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: April 24, 2002 By: /s/ Fredric D. Price --------------------- Fredric D. Price Chairman and Chief Executive Officer EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press Release of the Registrant dated April 22, 2002 EX-99 3 exhibit991.txt ARYPLASE PRESS RELEASE EXHIBIT 99.1 NEWS Contacts: Jeremy Price Sharon Karlsberg Manager, Investor Relations Vice President BioMarin Pharmaceutical Inc. Feinstein Kean Healthcare (415) 884-6777 (617) 577-8110 jprice@biomarinpharm.com skarlsberg@fkhealth.com For Immediate Release: BioMarin Initiates Phase 2 Trial of AryplaseTM Enzyme Replacement Therapy for MPS VI Novato, CA, April 22nd, 2002 - BioMarin Pharmaceutical Inc. (Nasdaq and Swiss SWX New Market: BMRN) today announced that it began dosing patients last month in a Phase 2 clinical trial of Aryplase (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B), an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI). MPS VI, also known as Maroteaux-Lamy syndrome, is a life-threatening lysosomal storage disorder for which no specific drug treatments currently exist. In September 2001, BioMarin reported positive safety and enzyme activity data from the Company's Phase 1 clinical trial of Aryplase. The primary objective of this open-label, multi-national Phase 2 clinical trial will be to evaluate the efficacy, safety and pharmacokinetics of weekly intravenous infusions of 1.0 mg/kg of Aryplase in 10 MPS VI patients. This dose represents the higher level of two doses administered in the six-patient Phase 1 trial. Stuart Swiedler, M.D., Ph.D., BioMarin's Vice President, Clinical Affairs, said, "Our goal is to assemble a comprehensive set of clinical data that will lead to the timely advancement of an effective treatment for this debilitating and currently untreatable genetic disease. We look forward to reporting results from this trial in the first quarter of 2003. Subsequently, if data from the Phase 2 trial demonstrate positive safety and efficacy outcomes, we anticipate the initiation of a pivotal Phase 3 trial." John Jost, Ph.D., BioMarin's Vice President, Manufacturing, added, "Clinical materials for the Phase 2 trial were produced in our recently upgraded clinical manufacturing facility, which will also produce the materials for the Phase 3 clinical program. Key modifications to the Aryplase manufacturing process have resulted in an approximately five-fold increase in plant productivity." BioMarin has received orphan drug and fast track designations for Aryplase for the treatment of MPS VI from the U.S. Food and Drug Administration, and the European Commission has designated Aryplase for the treatment of MPS VI as an orphan medicinal product. Aryplase Phase 1 Results In September 2001, BioMarin reported results from a randomized, double-blind six-patient Phase 1 clinical trial of Aryplase. The primary objective of this trial was to evaluate the safety of Aryplase at two dose levels: 0.2 mg/kg and 1.0 mg/kg. The enzyme was well tolerated by all six patients during the initial 24-week treatment stage, and key findings included: o No treatment-related serious adverse events; o No significant allergic reactions to the enzyme infusions; o Urinary glycosaminoglycan (GAG) excretion was reduced by a mean of 70% and 55% in the high and low dose groups, respectively; o Reduced urinary GAG excretion was evident within three weeks of initiating treatment. The reduction in urinary GAGs indicates that Aryplase is breaking down the complex carbohydrate materials that otherwise accumulate in patients with MPS VI and lead to the debilitating and life-threatening symptoms of the disease. About MPS VI MPS VI is a life-threatening lysosomal storage disorder caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B). This deficiency leads to the accumulation of GAGs in the lysosomes, the digestive organs of the cell. The accumulation of GAGs in the lysosomes leads to progressive cellular, tissue and organ system dysfunction. Debilitating symptoms often include impaired cardiac and pulmonary function, delayed physical development, skeletal and joint deformities, impaired vision and hearing, sleep disorders, and reduced endurance. Depending on the severity of the disease, patients die from disease-related complications between childhood and early adulthood. BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic enzyme products to treat serious, life-threatening diseases and other conditions. This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including the prospects of Aryplase. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Results may differ materially depending on the progress of BioMarin's product programs, the data to be released when the ongoing Aryplase trial is unblinded, the results of current and proposed clinical trials, actions of regulatory authorities, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission such as 10Q, 10K and 8K reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. # # # -----END PRIVACY-ENHANCED MESSAGE-----